Literature DB >> 10773006

Cocaine potentiates ethanol-induced excitation of dopaminergic reward neurons in the ventral tegmental area.

E B Bunney1, S B Appel, M S Brodie.   

Abstract

The coabuse of cocaine and ethanol is one of the most frequently used substance abuse combinations in the United States. The dopamine (DA) neurons in the ventral tegmental area (VTA) are important in the rewarding mechanism of these two substances. Cocaine is known to block the reuptake of DA and serotonin (5-HT). At concentrations below 1 microM, cocaine preferentially blocks the reuptake of 5-HT compared with DA. We have previously shown that ethanol increases the firing rate of DA neurons in the VTA, and that this excitation is enhanced by 5-HT. Extracellular single-unit recordings were made from VTA dopaminergic neurons in coronal brain slices from young adult Fischer 344 rats. Cocaine (1-10 microM) reduced the spontaneous firing rate in VTA dopaminergic neurons in a concentration-related manner. A lower concentration of cocaine (500 nM), which is a concentration that is pharmacologically relevant in addicts, produced only a very small decrease in the firing rate of VTA neurons but potentiated ethanol excitation of these neurons. Higher concentrations of cocaine (1 microM) did not enhance ethanol excitation. Ethanol-induced excitation was potentiated by the higher concentrations of cocaine (1 and 2 microM) in the presence of the D(2) receptor antagonist sulpiride (1 microM). Furthermore, cocaine potentiation of ethanol-induced excitation was reversed by ketanserin (2 microM), a 5-HT(2) antagonist. The enhanced ethanol excitation of VTA dopaminergic neurons caused by cocaine may partially explain the high incidence of the coabuse of these two substances.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773006

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Synergistic self-administration of ethanol and cocaine directly into the posterior ventral tegmental area: involvement of serotonin-3 receptors.

Authors:  Zheng-Ming Ding; Scott M Oster; Sheketha R Hauser; Jamie E Toalston; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  J Pharmacol Exp Ther       Date:  2011-10-19       Impact factor: 4.030

2.  Cocaine influences alcohol-seeking behavior and relapse drinking in alcohol-preferring (P) rats.

Authors:  Sheketha R Hauser; Jessica A Wilden; Gerald A Deehan; William J McBride; Zachary A Rodd
Journal:  Alcohol Clin Exp Res       Date:  2014-10       Impact factor: 3.455

3.  Microinjection of glycine into the ventral tegmental area selectively decreases ethanol consumption.

Authors:  Jing Li; Hong Nie; Weiliang Bian; Vaidehi Dave; Patricia H Janak; Jiang-Hong Ye
Journal:  J Pharmacol Exp Ther       Date:  2012-01-11       Impact factor: 4.030

4.  Cocaine exposure in vitro induces apoptosis in fetal locus coeruleus neurons by altering the Bax/Bcl-2 ratio and through caspase-3 apoptotic signaling.

Authors:  S Dey; C F Mactutus; R M Booze; D M Snow
Journal:  Neuroscience       Date:  2006-11-03       Impact factor: 3.590

Review 5.  Presynaptic control of serotonin on striatal dopamine function.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Psychopharmacology (Berl)       Date:  2010-10-16       Impact factor: 4.530

6.  Interactions between ethanol and cocaine, amphetamine, or MDMA in the rat: thermoregulatory and locomotor effects.

Authors:  Sami Ben Hamida; Erin Plute; Brigitte Cosquer; Christian Kelche; Byron C Jones; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2007-11-27       Impact factor: 4.415

7.  The effects of combined intravenous cocaine and ethanol self-administration on the behavioral and amino acid profile of young adult rats.

Authors:  Alberto Marcos; Mario Moreno; Javier Orihuel; Marcos Ucha; Ana Mª de Paz; Alejandro Higuera-Matas; Roberto Capellán; Antonio L Crego; María-Rosa Martínez-Larrañaga; Emilio Ambrosio; Arturo Anadón
Journal:  PLoS One       Date:  2020-03-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.